KR101004140B1 - Method for preparating external application to the skin using a hydrogel - Google Patents

Method for preparating external application to the skin using a hydrogel Download PDF

Info

Publication number
KR101004140B1
KR101004140B1 KR1020100073451A KR20100073451A KR101004140B1 KR 101004140 B1 KR101004140 B1 KR 101004140B1 KR 1020100073451 A KR1020100073451 A KR 1020100073451A KR 20100073451 A KR20100073451 A KR 20100073451A KR 101004140 B1 KR101004140 B1 KR 101004140B1
Authority
KR
South Korea
Prior art keywords
hydrogel
skin
weight
urethane
external preparation
Prior art date
Application number
KR1020100073451A
Other languages
Korean (ko)
Inventor
김정현
Original Assignee
주식회사 에코산업
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 에코산업 filed Critical 주식회사 에코산업
Priority to KR1020100073451A priority Critical patent/KR101004140B1/en
Application granted granted Critical
Publication of KR101004140B1 publication Critical patent/KR101004140B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F13/0283—Apparatus or processes for manufacturing adhesive dressings or bandages for making adhesive or cohesive tape or fabrics therefor, e.g. coating or mechanical treatments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F13/0289—Apparatus or processes for manufacturing adhesive dressings or bandages manufacturing of adhesive dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

PURPOSE: A method for manufacturing an external use skin formulation using hydrogel is provided to smoothly transfer anti-inflammatory agent to the skin. CONSTITUTION: A method for manufacturing an external use skin formulation for treating contusion or inflammation and relieving pain comprises: a step of applying adhesive(15) on one side of urethane(10) and attaching by laminating with non-woven fabric; a step of mixing 0.1-5 weight parts of anti-inflammatory agent to 100 weight parts of hydrogel to obtain a functional hydrogel(25); a step of applying the hydrogel on one side of the fabric or release film(30); a step of attaching the film to the fabric through a roller; a step of maturing; and a step of cutting the fabric in an external use skin formulation.

Description

하이드로겔을 이용한 피부외용제의 제조방법{METHOD FOR PREPARATING EXTERNAL APPLICATION TO THE SKIN USING A HYDROGEL}METHOD FOR PREPARATING EXTERNAL APPLICATION TO THE SKIN USING A HYDROGEL}

본 발명은 하이드로겔을 이용한 피부외용제의 제조방법에 관한 것으로, 피부온도에 감응하여 겔상태의 기능성 하이드로겔을 졸상태 즉, 액체상태로 변환시켜 소염진통제를 피부에 원활히 전달시키도록 한 하이드로겔을 이용한 피부외용제의 제조방법에 관한 것이다.The present invention relates to a method for preparing a skin external preparation using a hydrogel, wherein the hydrogel converts a gel functional hydrogel into a sol state, that is, a liquid state in response to skin temperature, so that an anti-inflammatory analgesic agent is smoothly delivered to the skin. It relates to a method for producing the external skin preparations used.

전신 또는 국부에서 약효를 얻기 위해서 경피 투과 제제의 여러가지 형태를 이용하여 약물을 피부를 통해 흡수시키는 것이 행하여지고 있다. 이러한 경피 투과법은 종래의 경구 투여법에 비해 여러 가지 장점이 있을 수 있다. Absorption of the drug through the skin is carried out using various forms of transdermal penetration preparations in order to obtain medicinal effects systemically or locally. Such transdermal penetration may have several advantages over conventional oral administration.

예를 들면 경구 투여시 많은 약물이 간장의 대사작용으로 많은 양이 분해되고, 이러한 결과로 과량의 약물을 복용함으로 위장장애 등과 같은 부작용을 나타내고 있다. 만일 경피 투과법을 이용한다면 이와 같은 부작용을 최소화 할 수 있고, 약물의 제어가 가능하며, 여러번 복용하는 번거로움을 줄일수 있는 장점을 가진다. For example, during oral administration, many drugs are degraded by metabolism of the liver, and as a result, side effects such as gastrointestinal disorder are indicated by taking an excessive amount of drugs. If transdermal penetration is used, such side effects can be minimized, the drug can be controlled, and the hassle of taking multiple doses is reduced.

특히, 경구제의 경우 장기간 복용함에 따른 부작용은 더 심각하며, 일반적으로 나타나는 소화기성 궤양, 장출혈, 위출혈 등의 부작용이 악화되어 더 큰 병을 일으킬 수 있는 문제점이 있었다.In particular, in the case of oral drugs, the side effects of taking a long time is more serious, there are problems that can cause a greater illness by the worse side effects such as gastrointestinal ulcers, intestinal bleeding, gastric bleeding.

이를 해소하고자 위의 경피 투과법을 이용하는 파스형태의 외용제를 사용하게 되는데, 대부분의 외용제는 진통소염성분이 외부와 노출된 구조이며, 이에 따라 진통소염성분을 일시적으로 피부에 전달해주는 효과는 있으나 진통소염성분이 외부로 증발하는 등 그 효과가 오래가지 못하였으며, 결국 소비자는 외용제를 계속해서 바꿔 부착하여야 하는 번거러움이 있을 뿐 아니라 이 경우에도 많은 량의 진통소염성분이 피부로 전달되지 못하는 문제점이 있었다.In order to solve this problem, the external form of the pars form using the percutaneous permeation method is used. Most of the external preparations have an analgesic anti-inflammatory component exposed to the outside, and thus, the analgesic anti-inflammatory component is temporarily transmitted to the skin, but it is analgesic. The anti-inflammatory ingredients did not last long, such as evaporation to the outside, and in the end, consumers had to constantly change the external preparations and attached them, and even in this case, a large amount of analgesic anti-inflammatory ingredients could not be delivered to the skin. .

또한, 이로 인해 외용제의 구입비용 부담과 더불어 외용제의 부착에 따른 시간대비 효과가 미흡한 문제점이 있었다.In addition, due to this, there was a problem in that the cost of purchasing the external preparation and the effect of the external preparation due to the attachment of the external preparation were insufficient.

본 발명은 상기한 문제점을 해결하기 위하여 창안된 것으로, 본 발명의 목적은 기능성 하이드로겔이 라미네이팅된 우레탄에 의해 외부와 차단되어져 외부온도에 민감하게 반응하지 않은 채 피부온도에 의해 반응하여 졸상태 즉, 액체상태로 변환되어진 후 진통소염제를 피부에 원활히 전달시킬 수 있도록 한 하이드로겔을 이용한 피부외용제의 제조방법을 제공하는 데 있다.The present invention was devised to solve the above problems, and an object of the present invention is that the functional hydrogel is blocked from the outside by laminated urethane and reacts with the skin temperature without reacting sensitively to the outside temperature, namely sol state. In addition, the present invention provides a method for preparing an external preparation for skin using a hydrogel that can be delivered to the skin after being converted into a liquid state.

또한, 본 발명의 다른 목적은 장시간 부착하여 사용하더라도 진통소염제의 계속적인 용출로 진통 및 소염효과를 얻을 수 있도록 한 하이드로겔을 이용한 피부외용제의 제조방법을 제공하는 데 있다.In addition, another object of the present invention is to provide a method for preparing an external preparation for skin using a hydrogel to obtain analgesic and anti-inflammatory effects by continuous dissolution of an analgesic anti-inflammatory agent even when used for a long time.

또한, 본 발명의 또 다른 목적은 피부외용제에 로고, 캐릭터 및 상표 등 특정 형상의 표장을 인쇄하여 사용시 광고 및 홍보효과를 얻을 수 있도록 한 하이드로겔을 이용한 피부외용제의 제조방법을 제공하는 데 있다.In addition, another object of the present invention is to provide a method for producing a skin external preparation using a hydrogel to obtain the advertising and promotion effect when using a specific shape such as logo, character and trademark on the skin external preparation.

상기의 목적을 달성하기 위한 본 발명은 타박상 또는 염증 질환의 치료 및 진통 완화를 위해 피부에 부착하는 피부외용제의 제조방법에 있어서, 우레탄(10)의 일면에 접착제(15)를 도포한 후 부직포(20)를 밀착시키고 라미네이팅하여 서로 접착시키는 단계와, 하이드로겔 100중량부에 진통소염제 0.1~5중량부를 혼합하여 기능성 하이드로겔(25)을 조성하는 단계와, 조성된 졸상태의 상기 기능성 하이드로겔(25)을 상기 우레탄(10)과 접착된 상기 부직포(20)의 일면 또는 이형용 필름(30)의 일면에 도포한 후 롤링기를 통해 상기 필름(30)을 상기 부직포(20)에 합포시키는 단계와, 합포 후 2~4일간 50~80℃의 온도로 숙성시킨 다음 다시 1~3일간 건조시켜 졸 상태의 기능성 하이드로겔(25)을 반고체상태의 겔로 형성하는 단계와, 상기 단계를 거친 후 생산하고자 하는 피부외용제의 형상으로 재단하는 단계로 이루어진 것을 특징으로 한다.In order to achieve the above object, the present invention provides a skin external preparation for adhering to the skin for the treatment of bruises or inflammatory diseases and pain relief, after applying the adhesive 15 to one surface of the urethane (10) 20) in close contact and laminating to adhere to each other, 0.1 to 5 parts by weight of the analgesic anti-inflammatory agent to 100 parts by weight of the hydrogel to form a functional hydrogel 25, and the sol state of the functional hydrogel ( 25) applying one surface of the nonwoven fabric 20 or one surface of the release film 30 adhered to the urethane 10 and then laminating the film 30 to the nonwoven fabric 20 through a rolling machine; Aged 2 to 4 days at a temperature of 50 ~ 80 ℃ and then dried again for 1 to 3 days to form a sol functional hydrogel (25) in a semi-solid gel, and after the step to produce skin It characterized by comprising the steps of cutting the shape of the solvent.

여기서, 상기 하이드로겔은 Polyacrylic acid 40~60중량%와, Glycerin 10~40중량%와, 물 10~40중량%와, Sodium hydroxide 1~10중량%와, Agar 0.1~3중량%와, Polysorbate60 0.1~3중량%로 조성되어 피부온도에 감응하여 상기 진통소염제를 피부에 전달하도록 이루어진 것이 바람직하다.Here, the hydrogel is 40 to 60% by weight of Polyacrylic acid, 10 to 40% by weight of Glycerin, 10 to 40% by weight of water, 1 to 10% by weight of sodium hydroxide, 0.1 to 3% by weight of Agar, and Polysorbate 60 0.1 It is preferably made up to ~ 3% by weight made to deliver the analgesic anti-inflammatory agent to the skin in response to the skin temperature.

이때, 상기 기능성 하이드로겔(25)에는 시원한 느낌이 들도록 하이드로겔 100중량부 대비 멘톨 0.1~5중량부가 더 혼합되어 조성되는 것이 바람직하다.At this time, the functional hydrogel 25 is preferably composed by mixing 0.1 to 5 parts by weight of menthol relative to 100 parts by weight of hydrogel so as to feel cool.

한편, 상기 단계를 거쳐 제조된 피부외용제가 색상을 띄도록 상기 우레탄(10)과 부직포(20)를 접착시키기 전에 상기 우레탄(10) 또는 부직포(20)를 다양한 색상으로 염색 또는 실크인쇄하여 색상을 띄도록 가공하는 단계를 더 거치는 것이 바람직하다.Meanwhile, before the urethane 10 and the nonwoven fabric 20 are adhered so that the skin external preparation prepared through the above steps has a color, the urethane 10 or the nonwoven fabric 20 is dyed or silk printed in various colors to color. It is desirable to further go through the processing step to stand out.

상기와 같이 구성된 본 발명에 따르면, 겔상태의 기능성 하이드로겔이 외부온도에 반응하지 않은 채 피부온도에 반응하여 졸상태 즉, 액체상태로 변환되어진 후 진통소염제를 피부에 원활히 전달시키게 된다.According to the present invention configured as described above, the functional hydrogel in the gel state is not reacted to the external temperature is converted to the sol state, that is, the liquid state after the reaction to the skin temperature to smoothly deliver the analgesic anti-inflammatory agent to the skin.

또한, 장시간 부착하여 사용하더라도 진통소염제의 계속적인 용출로 진통 및 소염효과를 얻을 수 있게 되고, 또한, 피부외용제에 로고, 캐릭터 및 상표 등 특정 형상의 표장을 인쇄하여 사용시 광고 및 홍보효과를 얻을 수 있게 된다.In addition, even if it is used for a long time, it is possible to obtain analgesic and anti-inflammatory effect by continuous dissolution of analgesic anti-inflammatory drugs, and also to obtain advertising and promotion effects by printing a specific shape such as logo, character and trademark on the external skin preparation. Will be.

도 1은 본 발명에 의한 피부외용제의 구조를 보인 단면상태도,
도 2는 본 발명에 의한 피부외용제의 사용상태도.1 is a cross-sectional view showing the structure of the external preparation for skin according to the present invention,
Figure 2 is a state of use of the external preparation for skin according to the present invention.

이하, 첨부된 도면을 참조하여 본 발명의 하이드로겔을 이용한 피부외용제의 제조방법을 상세히 설명한다.Hereinafter, with reference to the accompanying drawings will be described in detail a method for producing a skin external preparation using a hydrogel of the present invention.

본 발명에 의한 하이드로겔을 이용한 피부외용제는 타박상 등의 통증 완화나 염증 질환의 치료 또는 진통 완화를 위해 피부에 부착하여 사용하는 피부외용제로서, 흔히 사용된 파스와 같은 형태로 제조되어 진다.The external skin preparation using the hydrogel according to the present invention is an external skin preparation used to attach to the skin to alleviate pain such as bruises, treat inflammatory diseases, or alleviate analgesic, and is prepared in the form of a commonly used paste.

상기 피부외용제는 겔상태로 기능성 하이드로겔을 구비함과 아울러 라미네이팅된 우레탄과 부직포의 구조로 인해 장시간 사용시에도 하이드로겔에 혼합된 진통소염제를 계속하여 용출시킬 수 있어 기존의 파스에 비해 월등히 향상된 효과를 얻을 수 있게 된다.The external preparation for the skin has a functional hydrogel in a gel state, and due to the structure of the laminated urethane and nonwoven fabric, it can continue to elute the analgesic anti-inflammatory agent mixed in the hydrogel even when used for a long time, thus significantly improving the effect compared to the conventional pars. You can get it.

상기 도면을 참조하여 이와 같은 본 발명의 피부외용제를 제조하는 방법을 살펴보면, 우레탄(10)과 부직포(20)의 접착단계와, 기능성 하이드로겔 조성단계와, 기능성 하이드로겔 도포단계와, 필름 부착단계와, 숙성 및 건조단계와, 재단단계로 이루어진다.Looking at the method for producing the skin external preparation of the present invention with reference to the drawings, the bonding step of the urethane (10) and the nonwoven fabric 20, the functional hydrogel composition step, the functional hydrogel coating step, the film attachment step And, aging and drying step, and the cutting step.

상기 우레탄(10)은 공기가 통풍되지 않아도 무방하나, 자체적으로 공기의 통풍이 가능한 구조로 이루어진 기능성 우레탄을 사용하도록 하여 높은 인장강도와 내구력을 갖도록 한다. 이러한 기능성 우레탄은 가격이 저렴하며, 자체적인 공기통풍기능으로 인해 별도로 공기의 통풍을 위해 통공을 형성하지 않아도 되는 이점이 있다.The urethane 10 may be air-ventilated, but has a high tensile strength and durability by using a functional urethane made of a structure capable of air ventilation itself. These functional urethanes are inexpensive and have the advantage of not having to form a separate through-hole for the air due to its own air vent function.

본 발명의 상기 우레탄(10)은 열가소성 폴리우레탄이나 열경화성 폴리우레탄을 사용할 수 있고, 또한 통풍기능을 갖는 우레탄 재질이면 가능하다.The urethane 10 of the present invention may be a thermoplastic polyurethane or a thermosetting polyurethane, and may be a urethane material having a ventilation function.

상기 부직포(20)는 그 조직구조에 한정되지 않고, 단방향성 부직포나 양방향성 부직포를 포함하며, 실이 엮여져 있는 복합부직포를 사용할 수 있다.The nonwoven fabric 20 is not limited to its organizational structure, and may include a unidirectional nonwoven fabric or a bidirectional nonwoven fabric, and a composite nonwoven fabric in which threads are woven.

상기 접착단계에서는 상기 우레탄(10)과 부직포(20)는 접착제(15)로 접착시켜 적층시키는 것으로, 우레탄(10)의 일면에 접착제(15)를 도포한 후 부직포(20)를 밀착시킨 상태에서 라미네이팅하여 접착시킨다.In the bonding step, the urethane 10 and the nonwoven fabric 20 are laminated by bonding with the adhesive 15, in which the nonwoven fabric 20 is in close contact after applying the adhesive 15 to one surface of the urethane 10. Laminate and bond.

상기 접착제(15)로는 핫멜트(hot melt)를 사용하면 된다.As the adhesive 15, hot melt may be used.

그리고, 상기 부직포(20)의 일면 또는 이형용 필름(30)의 일면에는 상기 기능성 하이드로겔(25)이 도포되는데, 이러한 기능성 하이드로겔(25)은 하이드로겔 100중량부 대비 진통소염제 0.1~5중량부가 혼합되어 조성되어 진다.In addition, the functional hydrogel 25 is applied to one surface of the nonwoven fabric 20 or one surface of the release film 30. The functional hydrogel 25 has 0.1 to 5 parts by weight of an analgesic anti-inflammatory agent based on 100 parts by weight of the hydrogel. It is mixed and composed.

상기 기능성 하이드로겔(25)은 졸 상태임에 따라 상기 부직포(20)에 도포한 경우 흘러내리게 되어 대부분이 부직포(20)로부터 분리되어져 소비자가 제품을 사용하는 과정에서 손 등에 기능성 하이드로겔(25)이 묻어나는 등 불편한 점을 해소하기 위해 겔상태로 형성하게 된다.Since the functional hydrogel 25 is in a sol state, when applied to the nonwoven fabric 20, the hydrogel 25 flows down, and most of the functional hydrogel 25 is separated from the nonwoven fabric 20. It is formed in a gel state to relieve the discomfort such as buried.

즉, 상기 졸 상태의 기능성 하이드로겔(25)은 도포 후 2~4일간 50~80℃의 온도로 숙성시킨 다음 다시 1~3일간 건조시켜 겔상태로 형성하는 단계를 거치게 되는 것이며, 이 단계를 거친 후 비로소 겔상태의 기능성 하이드로겔(25)이 도포된 부직포(일면과 타면에 각각 필름과 우레탄이 부착되어 있음)를 재단하게 된다.That is, the sol functional hydrogel 25 is aged at a temperature of 50 ~ 80 ℃ for 2 to 4 days after application and then dried again for 1 to 3 days to form a gel state, this step After roughing, the non-woven fabric (the film and urethane are attached to one side and the other side, respectively) coated with the functional hydrogel 25 in a gel state is cut.

이때, 상기 졸 상태의 기능성 하이드로겔(25)을 도포한 후에는 롤링기를 통해 상기 필름(30)을 상기 부직포(20)에 합포시키는 단계를 거치게 되고, 이 후 상기 숙성 및 건조단계를 거치게 된다.In this case, after applying the sol functional hydrogel 25 is subjected to the step of laminating the film 30 to the nonwoven fabric 20 through a rolling machine, and then undergoes the aging and drying step.

상기 재단단계에서는 건조가 완료된 상태에서 생산하고자 하는 피부외용제의 여러 형상으로 재단하게 되는 것이다.In the cutting step is to cut into various shapes of the skin external preparation to be produced in a dry state.

여기서, 본 발명에 사용되는 상기 하이드로겔은 피부온도에 감응하도록 조성되어 체온에 의해 진통소염제 성분을 피부에 전달하도록 이루어진 물질로서, Polyacrylic acid 40~60중량%와, Glycerin 10~40중량%와, 물 10~40중량%와, Sodium hydroxide 1~10중량%와, Agar 0.1~3중량%와, Polysorbate60 0.1~3중량%로 조성되어 진다.Here, the hydrogel used in the present invention is a substance configured to respond to the skin temperature to deliver the analgesic anti-inflammatory component to the skin by body temperature, 40 to 60% by weight of Polyacrylic acid, 10 to 40% by weight of Glycerin, It is composed of 10 to 40% by weight of water, 1 to 10% by weight of sodium hydroxide, 0.1 to 3% by weight of Agar, and 0.1 to 3% by weight of Polysorbate60.

이때, 상기 Sodium hydroxide은 체온, 즉 피부온도에 감응하여 겔상태의 하이드로겔을 녹여 유동상태로 변화시킴으로써 결국 진통소염제를 피부로 잘 전달되게 하는 역할을 하게 되는 것이다.At this time, the sodium hydroxide melts the hydrogel in a gel state in response to body temperature, that is, the skin temperature, and changes the fluid state so that the analgesic anti-inflammatory agent is well delivered to the skin.

따라서, 본 발명의 피부외용제를 부착하게 되면, 부직포에 라미네이팅된 우레탄에 의해 외부와 차단되어져 외부온도에 민감하게 반응하지 않은 채 겔상태를 유지하게 되며, 이 상태에서 피부온도 즉, 체온에 의해 하이드로겔이 반응하면서 겔상태의 기능성 하이드로겔을 유동상태로 변화시키도록 하여 하이드로겔에 함께 혼합되어 있는 진통소염제를 피부에 침투시키게 되는 것이다.Therefore, when the external preparation of the skin of the present invention is attached, it is blocked from the outside by the urethane laminated on the nonwoven fabric and maintains the gel state without reacting sensitively to the external temperature. As the gel reacts, the functional hydrogel in the gel state is changed into a fluid state so that the analgesic anti-inflammatory agent mixed with the hydrogel is infiltrated into the skin.

여기서, 본 발명의 하이드로겔에 혼합되는 상기 진통소염제는 비스테로이드성 진통소염제로서, 아스피린, 이부프로펜, 나프록센, 케토프로펜, 살리실산, 캡사이신, 피록시감, 페노프로펜, 메페남산, 아세트아미노펜 제제 중 하나 이상 선택된 것이 바람직하다.Here, the analgesic anti-inflammatory agent mixed in the hydrogel of the present invention is a nonsteroidal analgesic anti-inflammatory agent, aspirin, ibuprofen, naproxen, ketoprofen, salicylic acid, capsaicin, pyrigam, phenopropene, mephenamic acid, acetaminophen formulations It is preferred that at least one of them be selected.

그리고, 본 발명의 기능성 하이드로겔(25)에는 혈행 개선을 위해 상기 하이드로겔 100중량부 대비 토코페롤 0.1~5중량부가 더 혼합될 수 있으며, 또한 피부외용제를 피부에 부착하여 사용하는 경우 시원한 느낌이 들도록 하이드로겔 100중량부 대비 멘톨 0.1~5중량부가 더 혼합되어 조성되는 것이 바람직하다.In addition, the functional hydrogel 25 of the present invention may be mixed 0.1 to 5 parts by weight of tocopherol more than 100 parts by weight of the hydrogel to improve blood circulation, and also to feel a cool feeling when using the external application to the skin It is preferable that 0.1-5 parts by weight of menthol is further mixed with 100 parts by weight of the hydrogel.

이때, 상기 멘톨은 만성 통증 질환자를 치료하는 경우 적합하며, 적은 량으로도 충분히 시원한 효과를 볼 수 있음에 따라 가능한한 너무 많은 량을 혼합시키지 않도록 한다.At this time, the menthol is suitable when treating a chronic pain disease, and do not mix too much amount as much as possible because the effect can be sufficiently cool even with a small amount.

아래의 [표1]과 [표2]는 본 발명의 진통소염제의 용출시험 결과를 보인 표로서, [표1] 및 [표2]를 보면, 용출된 진통소염제(유효성분)의 측정값이 1시간에 비해 2시간이 지난 후 ⅓이상 증가하고 있음을 알 수 있고, 이는 본 발명과 같이 조성된 하이드로겔과, 우레탄 및 부직포가 적층된 구조에 의한 결과이다.[Table 1] and [Table 2] below show the dissolution test results of the analgesic anti-inflammatory drugs of the present invention. [Table 1] and [Table 2] shows the measured values of the eluted analgesic anti-inflammatory agents (active ingredients). It can be seen that after 2 hours compared to 1 hour is increased by more than ,, which is a result of the hydrogel, urethane and nonwoven fabric laminated in the present invention.

[표1]Table 1

Figure 112010049205061-pat00001

Figure 112010049205061-pat00001

[표2][Table 2]

Figure 112010049205061-pat00002

Figure 112010049205061-pat00002

이와 같이, 본 발명의 피부외용제는 2~3시간 이상 사용하여도 진통소염제가 용출되도록 한 것으로, 일반적인 파스의 구조 또는 조성물로는 본 발명과 같은 효과를 기대할 수 없는 것이다.As described above, the external skin preparation of the present invention allows the analgesic anti-inflammatory agent to be eluted even when used for 2 to 3 hours or more, and it is impossible to expect the same effects as the present invention with the structure or composition of general pars.

특히, 일반적인 파스는 진통소염제 성분이 외부온도에 반응하거나 쉽게 공기중으로 증발하게 됨으로써 대부분 1시간 이내에 진통소염제 성분이 없어져 그 효과를 장시간 얻기가 어려웠으나, 본 발명의 피부외용제는 장시간동안 계속적으로 효과를 볼 수 있게 된 것이다. In particular, the general parsing component of the analgesic anti-inflammatory agent reacts with the external temperature or easily evaporates into the air, and thus, the analgesic anti-inflammatory agent is almost eliminated within one hour, so it is difficult to obtain the effect for a long time. I can see it.

한편, 본 발명의 피부외용제는 특정한 색상을 띄도록 제작할 수 있는데, 이 경우에는 상기 우레탄(10)과 부직포(20)를 접착시키는 접착단계 전에 상기 우레탄(10) 또는 부직포(20)를 염색하는 가공단계를 거치면 된다.On the other hand, the skin external preparation of the present invention can be produced to have a particular color, in this case, the process of dyeing the urethane 10 or nonwoven fabric 20 before the bonding step of bonding the urethane 10 and the nonwoven fabric 20 Just go through the steps.

이때, 상기 우레탄(10) 또는 부직포(20)는 다양한 색상으로 염색할 수 있으며, 염색외에도 실크인쇄하여 색상을 띄도록 할 수 있다.At this time, the urethane 10 or non-woven fabric 20 can be dyed in a variety of colors, in addition to dyeing can be printed by silk printing to bring out the color.

또한, 상기 우레탄(10) 또는 부직포(20)에 특정 로고나 캐릭터, 상표 등의 표장을 인쇄할 수 있으며, 인쇄방식 외에도 표면이 굴곡을 갖도록 음각 또는 양각으로 형성시킬 수도 있다.In addition, the urethane 10 or the nonwoven fabric 20 may be printed on the logo, such as a specific logo, character, trademark, etc., in addition to the printing method may be formed in an intaglio or embossed to have a curved surface.

10: 우레탄 15: 접착제
20: 부직포 25: 기능성 하이드로겔
30: 필름10: urethane 15: adhesive
20: nonwoven fabric 25: functional hydrogel
30: film

Claims (4)

타박상 또는 염증 질환의 치료 및 진통 완화를 위해 피부에 부착하는 피부외용제의 제조방법에 있어서,
우레탄(10)의 일면에 접착제(15)를 도포한 후 부직포(20)를 밀착시키고 라미네이팅하여 서로 접착시키는 단계와,
하이드로겔 100중량부에 진통소염제 0.1~5중량부를 혼합하여 기능성 하이드로겔(25)을 조성하는 단계와,
조성된 졸상태의 상기 기능성 하이드로겔(25)을 상기 우레탄(10)과 접착된 상기 부직포(20)의 일면 또는 이형용 필름(30)의 일면에 도포한 후 롤링기를 통해 상기 필름(30)을 상기 부직포(20)에 합포시키는 단계와,
합포 후 2~4일간 50~80℃의 온도로 숙성시킨 다음 다시 1~3일간 건조시켜 졸 상태의 기능성 하이드로겔(25)을 반고체상태의 겔로 형성하는 단계와,
상기 단계를 거친 후 생산하고자 하는 피부외용제의 형상으로 재단하는 단계로 이루어지고,
상기 단계를 거쳐 제조된 피부외용제가 색상을 띄도록 상기 우레탄(10)과 부직포(20)를 접착시키기 전에 상기 우레탄(10) 또는 부직포(20)를 다양한 색상으로 염색 또는 실크인쇄하여 색상을 띄도록 가공하는 단계를 더 거치게 되며,
상기 하이드로겔은 Polyacrylic acid 40~60중량%와, Glycerin 10~40중량%와, 물 10~40중량%와, Sodium hydroxide 1~10중량%와, Agar 0.1~3중량%와, Polysorbate60 0.1~3중량%로 조성되어 피부온도에 감응하여 상기 진통소염제를 피부에 전달하도록 이루어진 것을 특징으로 하는 하이드로겔을 이용한 피부외용제의 제조방법.
In the manufacturing method of the external preparation for skin, which is attached to the skin for the treatment of bruises or inflammatory diseases and relieve pain
After the adhesive 15 is applied to one surface of the urethane (10) and the non-woven fabric 20 is in close contact and laminating to adhere to each other,
Preparing a functional hydrogel 25 by mixing 0.1-5 parts by weight of an analgesic anti-inflammatory agent to 100 parts by weight of the hydrogel;
The functional hydrogel 25 in a sol state is coated on one surface of the nonwoven fabric 20 or one surface of a release film 30 adhered to the urethane 10, and then the film 30 is applied through a rolling machine. Compounding the nonwoven fabric 20,
Aging for 2 to 4 days at 50 ~ 80 ℃ after drying, and then dried again for 1 to 3 days to form a sol functional hydrogel (25) as a semi-solid gel,
After the above step is made of a step of cutting to the shape of the skin external preparation to be produced,
Dyeing or silk-printing the urethane 10 or non-woven fabric 20 in a variety of colors before the urethane (10) and the nonwoven fabric 20 so that the skin external preparation prepared through the above steps to have a color to make the color. Going through more processing steps,
The hydrogel is 40 to 60% by weight of Polyacrylic acid, 10 to 40% by weight of Glycerin, 10 to 40% by weight of water, 1 to 10% by weight of sodium hydroxide, 0.1 to 3% by weight of Agar, and 0.1 to 3 of Polysorbate60. A method of preparing an external preparation for skin using a hydrogel, characterized in that the composition is prepared by weight percent to deliver the analgesic anti-inflammatory agent to the skin in response to skin temperature.
삭제delete 제1항에 있어서,
상기 기능성 하이드로겔(25)에는 시원한 느낌이 들도록 하이드로겔 100중량부 대비 멘톨 0.1~5중량부가 더 혼합되어 조성되는 것을 특징으로 하는 하이드로겔을 이용한 피부외용제의 제조방법.The method of claim 1,
The functional hydrogel 25 is a method for producing a skin external preparation using a hydrogel, characterized in that 0.1 to 5 parts by weight of menthol is further mixed with 100 parts by weight of hydrogel so as to feel cool. 삭제delete
KR1020100073451A 2010-07-29 2010-07-29 Method for preparating external application to the skin using a hydrogel KR101004140B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020100073451A KR101004140B1 (en) 2010-07-29 2010-07-29 Method for preparating external application to the skin using a hydrogel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100073451A KR101004140B1 (en) 2010-07-29 2010-07-29 Method for preparating external application to the skin using a hydrogel

Publications (1)

Publication Number Publication Date
KR101004140B1 true KR101004140B1 (en) 2010-12-27

Family

ID=43513411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100073451A KR101004140B1 (en) 2010-07-29 2010-07-29 Method for preparating external application to the skin using a hydrogel

Country Status (1)

Country Link
KR (1) KR101004140B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102169792B1 (en) 2020-04-20 2020-10-26 주식회사 메디셀 insulin supplying patch composition for diabetes mellitus and patch manufacturing method using the same
KR102178353B1 (en) 2020-08-21 2020-11-13 주식회사 메디셀 patch composition for diabetes mellitus and patch manufacturing method using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100847222B1 (en) * 2007-01-04 2008-07-17 주식회사 엘지생활건강 Phase transition cosmetic transdermal delivery system with increased skin absorption

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100847222B1 (en) * 2007-01-04 2008-07-17 주식회사 엘지생활건강 Phase transition cosmetic transdermal delivery system with increased skin absorption

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102169792B1 (en) 2020-04-20 2020-10-26 주식회사 메디셀 insulin supplying patch composition for diabetes mellitus and patch manufacturing method using the same
KR102178353B1 (en) 2020-08-21 2020-11-13 주식회사 메디셀 patch composition for diabetes mellitus and patch manufacturing method using the same

Similar Documents

Publication Publication Date Title
KR101154327B1 (en) manufacturing method of hydrogel patch for wound-healing
CN100372526C (en) Warm poultice
CN101564383B (en) Skin external used patch
JP4086317B2 (en) Transdermal treatment system with thin application area and high flexibility, and method for manufacturing the same
EP3518864B1 (en) Kit and method for topical delivery of benefits
CN1946429B (en) Adhesive material
CN105473132A (en) Cataplasm and method for producing same
KR101004139B1 (en) Method for preparating atopy patch using a hydrogel
KR101372227B1 (en) Hydro-gel mask with hardened outer surface and making method of the same
JP4953508B2 (en) Delivery means for cosmetically active substances
CN105147443A (en) Thermochromic fever cooling patch and manufacturing method thereof
KR101004140B1 (en) Method for preparating external application to the skin using a hydrogel
CN101686950B (en) Poultice and process for producing the poultice
CN106102513A (en) Skin masking material
CN205548793U (en) Essential oil subsides
KR20110060571A (en) Powder adhered hanji hydrogel maskpack
KR101154328B1 (en) manufacturing method of hydrogel patch for treating the athlete's foot
CN101023995A (en) Novel plaster for treating stamotocace
KR20070011981A (en) Process and its main machines manufacturing the cataplasma
KR100708308B1 (en) Method for producing paleorange-colored adhesive sheet and one touch-cataplasm and system therefor
CN200980835Y (en) Easy-to-open and easy-to-stick type plaster
JP2886021B2 (en) Stable patch
KR20140024578A (en) A hydrogel patch for healing wound and a method of preparing the same
KR101675917B1 (en) Body painting pass a medical and a manufacturing method.
JP2540861B2 (en) Poultice

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20131219

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20141222

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20151120

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20171207

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20181220

Year of fee payment: 9